Carbapenem restriction and its effect on bacterial resistance in an intensive care unit of a teaching hospital

Iranian Journal of Pharmaceutical Research

Volumn 12, Issue 3, 2013, Pages 503-509

  Sistanizad, Mohammad ^a,b   Kouchek, Mehran ^b   Miri, Mohammad ^b   Goharani, Reza ^b   Solouki, Mehrdad ^b   Ayazkhoo, Ladan ^a   Foroumand, Masoumeh ^b   Mokhtari, Majid ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CARBAPENEM; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; DRUG USE; ESCHERICHIA COLI; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA; MICROBIOLOGY; NONHUMAN; PSEUDOMONAS AERUGINOSA;

EID: 84883751978     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Jensen TG, Kolmos HJ and Siboni K. Resistance problems in two university hospitals in Denmark. Int. J. Antimicrob Agents. (1999) 12: 71-73.
2. Mojtahedzadeh M and Mahmoudi L. Aminoglycoside Resistance in ICUs: Are We Running out of Drugs, for Bad Bugs. Iran. J. Pharm. Res. (2011) 10: 391-392.
3. Sarrafzadeh F and Sohrevardi SM. Evaluation of Bactereuria and Antimicrobial Susceptibility among Hospitalized Patients With and Without Catheter in Kerman Province- Iran in 2011. Iran. J. Pharm. Res. (2013) 12: 211-216.
4. Spellberg B, Powers JH, Brass EP, Miller LG and Edwards JE, Jr. Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. (2004) 38: 1279-1286.
5. Lee MK, Chiu CS, Chow VC, Lam RK and Lai RW. Prevalence of hospital infection and antibiotic use at a university medical center in Hong Kong. J. Hosp. Infect. (2007) 65: 341-347.
6. st century. Diagn Microbiol Infect Dis. (2008) 61: 110-128.
7. Alanis AJ. Resistance to antibiotics: are we in the post-antibiotic era? Arch. Med. Res. (2005) 36: 697-705.
8. Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S and Larson EL. Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. Clin. Infect. Dis. (2012) 55: 807-815.
9. Roberts RR, Hota B, Ahmad I, Scott RD, 2nd, Foster SD, Abbasi F, Schabowski S, Kampe LM, Ciavarella GG, Supino M, Naples J, Cordell R, Levy SB and Weinstein RA. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin. Infect. Dis. (2009) 49: 1175-1184.
10. Bennett PM and Hawkey PM. The future contribution of transposition to antimicrobial resistance. J. Hosp Infect. (1991) 18 Suppl A211-A221.
11. Erbay A, Colpan A, Bodur H, Cevik MA, Samore MH and Ergonul O. Evaluation of antibiotic use in a hospital with an antibiotic restriction policy. Int. J. Antimicrob Agents. (2003) 21: 308-312.
12. Shorr AF. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit. Care Med. (2009) 37: 1463-1469.
13. Sarrafzadeh F, Sohrevardi SM, Gharehghozli M and Ahmadinejad M. Detection of the Most Common Microorganisms and Their Resistance against Antimicrobials in Intubated Patients in an ICU in Kerman, Iran. Iran. J. Pharm. Res. (2010) 9: 437-443.
14. Gilbert DN and Edwards JE, Jr. Is there hope for the prevention of future antimicrobial shortages? Clin. Infect. Dis. (2002) 35: 215-216.
15. Shlaes DM and Moellering RC, Jr. The United States Food and Drug Administration and the end of antibiotics. Clin. Infect Dis. (2002) 34: 420-422.
16. Projan SJ. Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol. (2003) 6: 427-430.
17. Dellit TH, Owens RC, McGowan JE, Jr., Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M and Hooton TM. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. (2007) 44: 159-177.
18. Bjerrum L, Munck A, Gahrn-Hansen B, Hansen MP, Jarbol DE, Cordoba G, Llor C, Cots JM, Hernandez S, Lopez-Valcarcel BG, Perez A, Caballero L, von der Heyde W, Radzeviciene R, Jurgutis A, Reutskiy A, Egorova E, Strandberg EL, Ovhed I, Molstad S, Stichele RV, Benko R, Vlahovic-Palcevski V, Lionis C and Ronning M. Health Alliance for prudent antibiotic prescribing in patients with respiratory tract infections (HAPPY AUDIT) -impact of a non-randomised multifaceted intervention programme. BMC Fam Pract. (2011) 1252.
19. Weber JT. Appropriate Use of Antimicrobial DrugsA Better Prescription Is Needed. JAMA: J. American Medical Association. (2005) 294: 2354-2356.
20. Samore MH, Bateman K, Alder SC, Hannah E, Donnelly S, Stoddard GJ, Haddadin B, Rubin MA, Williamson J, Stults B, Rupper R and Stevenson K. Clinical Decision Support and Appropriateness of Antimicrobial PrescribingA Randomized Trial. JAMA: J. American Medical Association. (2005) 294: 2305-2314.
21. Perencevich EN, Stone PW, Wright SB, Carmeli Y, Fisman DN and Cosgrove SE. Raising standards while watching the bottom line: making a business case for infection control. Infect. Control Hosp. Epidemiol. (2007) 28: 1121-1133.
22. McKibben L, Horan TC, Tokars JI, Fowler G, Cardo DM, Pearson ML and Brennan PJ. Guidance on public reporting of healthcare-associated infections: recommendations of the Healthcare Infection Control Practices Advisory Committee. Infect Control Hosp. Epidemiol. (2005) 26: 580-587.
23. Ntagiopoulos PG, Paramythiotou E, Antoniadou A, Giamarellou H and Karabinis A. Impact of an antibiotic restriction policy on the antibiotic resistance patterns of Gram-negative microorganisms in an Intensive Care Unit in Greece. Int. J. Antimicrob Agents. (2007) 30: 360-365.
24. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control. (2004) 32: 470-485.
25. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett JG and Edwards J, Jr. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. (2008) 46: 155-164.
26. Schwaber MJ and Carmeli Y. Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA. (2008) 300: 2911-2913.
27. Patel G, Perez F and Bonomo RA. Carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii: assessing their impact on organ transplantation. Curr. Opin. Organ Transplant. (2010)
28. Pakyz AL, Oinonen M and Polk RE. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. (2009) 53: 1983-1986.
29. Xue XS, Wang B, Deng LJ and Kang Y. [Carbapenem restriction reduce the incidence of multidrug-resistant Acinetobacter baumannii in ventilator associated pneumonia]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. (2009) 21: 234-236.
30. th informational supplement M100-S19.
31. Vessal G, Afhami S, Gholami K, Shafaghi B and Yazdi SH. Evaluation of Antimicrobial Resistance Among Gram-Negative Isolates Collected from Intensive Care Units and Reliability of Routine Disc Susceptibility Tests at a Teaching Hospital in Tehran. Iran. J. Pharm. Res. (2006) 100-289.
32. Altunsoy A, Aypak C, Azap A, Ergonul O and Balik I. The impact of a nationwide antibiotic restriction program on antibiotic usage and resistance against nosocomial pathogens in Turkey. Int. J. Med. Sci. (2011) 8: 339-344.
33. Bantar C, Sartori B, Vesco E, Heft C, Saul M, Salamone F and Oliva ME. A hospitalwide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance. Clin. Infect. Dis. (2003) 37: 180-186.
34. Katsios CM, Burry L, Nelson S, Jivraj T, Lapinsky SE, Wax RS, Christian M, Mehta S, Bell CM and Morris AM. An antimicrobial stewardship program improves antimicrobial treatment by culture site and the quality of antimicrobial prescribing in critically ill patients. Crit. Care. (2012) 16: R216.
35. Ong DS, Jongerden IP, Buiting AG, Leverstein-van Hall MA, Speelberg B, Kesecioglu J and Bonten MJ. Antibiotic exposure and resistance development in Pseudomonas aeruginosa and Enterobacter species in intensive care units. Crit. Care Med. (2011) 39: 2458-2463.
36. White AC, Jr., Atmar RL, Wilson J, Cate TR, Stager CE and Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin. Infect. Dis. (1997) 25: 230-239.
37. Martin C, Ofotokun I, Rapp R, Empey K, Armitstead J, Pomeroy C, Hoven A and Evans M. Results of an antimicrobial control program at a university hospital. Am. J. Health Syst. Pharm. (2005) 62: 732-738.